TRANSPARENCY COUNCIL MEETING NO. 31/2023 AUGUST 7, 2023
1. darzalex (daratumumabum) - CONDITIONAL Indication: under drug program B.54. "Treatment of patients with plasmocytic myeloma (ICD-10: C90.0)". Decision-making problem: preparation of a position paper on the evaluation of the drug
2. Orgovyx (Relugolixum) CONDITIONAL Indication: advanced hormone-dependent prostate cancer Decision problem: preparing a position paper on the evaluation of the drug
3. Strensiq (asfotasum alfa) CONDITIONAL Indication: under the drug program "Treatment of bone symptoms in the course of pediatric hypophosphatasia (HPP) (ICD-10 E83.3) with asfotasum alfa" Decision problem: preparation of a position paper on the evaluation of the drug
4. "Program of rehabilitation and support of physical activity of residents in the Municipality of Gogolin for 2024- 2027",
"Program for early detection of hearing and vision defects in children in the Municipality of Gogolin for 2024-2027",
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
